Option Care Health expects up to a $70 million revenue hit in 2025 from Stelara pricing changes and biosimilar adoption, ...
Q3 2025 Management View John Rademacher, CEO, highlighted executive transitions, noting "Mike Shapiro stepped down as CFO, and Meenal Sethna joined us as CFO on October 1," and welcomed Stephen ...
Hosted on MSN
Biocon's biologics arm gets Health Canada approval for monoclonal antibody drug Yesintek
Mumbai, Oct. 23 -- Yesintek is ustekinumab injection and Yesintek I.V. is ustekinumab for injection, solution for intravenous infusion. These drugs are biosimilars of Stelara (ustekinumab injection) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback